We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Micro Ribonucleic Nucleic Acid Panel Assays Launched

By LabMedica International staff writers
Posted on 28 Sep 2015
Print article
Image: SensiFAST SYBR No-ROX Kit developed for fast, highly reproducible real-time Polymerase Chain Reactions (PCR) (Photo courtesy of Bioline).
Image: SensiFAST SYBR No-ROX Kit developed for fast, highly reproducible real-time Polymerase Chain Reactions (PCR) (Photo courtesy of Bioline).
A novel approach has been developed by combinations of micro ribonucleic nucleic acid (miRNA) specific reverse transcriptase and hemi-nested real-time polymerase chain reaction (PCR) primers that have been designed to maximize miRNA detection sensitivity and specificity.

The miRNA Panel Assays provide scientists with a convenient way to quickly analyze miRNAs that suggest a correlation with the dysregulations in various cancers, in maintenance, differentiation and reprogramming of stem cells and to look at circulating miRNAs that are regarded as a promising new class of biomarkers.

The real-time PCR assays use SensiSMART with SYBR Green (Bioline USA Inc.; Taunton, MA, USA) to enable detection of extremely low levels of miRNA with high specificity, allowing the discrimination between closely related miRNA sequences. This highly reproducible, sensitive platform has been validated independently by molecular diagnostic and pharmaceutical laboratories and showed superior performance to existing commercial assays.

The Bioline EPIK miRNA Panel Assays were developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of collaboration with MiRXES (Singapore). Marco Calzavara, president of Bioline, said, “The release of the EPIK miRNA Panel Assays follows the release of the ISOLATE II miRNA, Biofluids RNA, RNA/DNA/Protein and FFPE RNA/DNA Kits earlier this year and shows the continued commitment of Bioline to produce high quality miRNA kits to help researchers with miRNA expression profiling and quantification and in biomarker discovery.”

Richard L. Eberly, president of Meridian Life Science, Inc. (Cincinnati, OH, USA), the parent company, stated, "We are excited about the release of the EPIK miRNA Panel Assays and the enhanced performance they provide for our important life science customers in the molecular diagnostic and pharmaceutical laboratories and biotechnology companies. We remain committed to the continued expansion of the rapidly growing portfolio of highly specialized molecular biology products from Bioline.”

Related Links:

Bioline USA Inc.
MiRXES 
Meridian Life Science, Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.